Biotechnology

Filter

Current filters:

None

Popular Filters

1944 to 1968 of 2220 results

Faster-than-expected FDA approval of Roche’s vismodegib

31-01-2012

There was good news for Swiss drug major Roche's (ROG: SIX)subsidiary Genentech yesterday, when it received…

BiotechnologyCurisErivedgeGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

Cell Therapeutics updates on Pixuvri

30-01-2012

Seattle, USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has voluntarily withdrawn its…

BiotechnologyCell TherapeuticsNorth AmericaOncologyPixuvriRegulation

Irish pharma sees failures in ESRI report on use of pharmaceuticals

30-01-2012

A new report by Ireland’s Economic and Social Research Institute (ESRI) has recommended new ways…

BiotechnologyEuropePharmaceuticalPricingRegulation

Lower anemia drug sales hit Amgen profit

30-01-2012

Global independent biotech leader Amgen (Nasdaq: AMGN) reported fourth-quarter 2011 results with 3% growth…

AmgenBiotechnologyFinancial

GenVec extends research deal with Novartis

29-01-2012

US biopharma company GenVec (Nasdaq: GNVC) says that it has extended its research collaboration and license…

BiotechnologyGenVecNeurologicalNovartisPharmaceuticalResearch

Amgen to acquire US/German biotech firm

27-01-2012

Adding to the strong start this year for M&A activity in the Pharma/Biotech sector, USA-based Amgen (Nasdaq:…

AmgenBiotechnologyMergers & AcquisitionsMicrometOncology

Celgene to buy Avila; posts strong 4th-qtr results

27-01-2012

USA-based Celgene (Nasdaq: CELG) yesterday revealed that it has entered into a definitive merger deal…

Avila TherapeuticsBiotechnologyCelgeneFinancialMergers & AcquisitionsOncologyPharmaceutical

Prosensa raises 23 million euros

26-01-2012

Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases…

BiotechnologyFinancialProsensaRare diseasesResearch

Overview of biologic regulations in India

26-01-2012

Currently, all biologics in India, including innovative and copy biologics are approved as new drugs,…

Asia-PacificBiotechnologyGenericsRegulation

Deal-making declines as Pharma tighten its belt

26-01-2012

Overall pharmaceutical deal-making activity fell by 18% in 2011 as pharmaceutical companies cut R&D expenditure…

BiotechnologyGlobalLicensingPharmaceutical

Vivalis opens new lab for antibody discovery; posts 112% revenue hike

25-01-2012

French biotech firm Vivalis (NNYSE Euronext: VLS) says it has opened a new facility for partnered VIVA|Screen…

BiotechnologyEuropeFinancialResearchSanofi PasteurVivalis

Global biotechnology market set to exceed $320 billion by 2015, says GIA

25-01-2012

The biotechnology industry was adversely affected by the global financial crisis, with several leading…

BiotechnologyGlobalMarkets & MarketingMergers & AcquisitionsResearch

A new year and good news is rolling in already, says AusBiotech

25-01-2012

Last year ended on a high for Australian biotechnology industry policy - with the R&D Tax Incentive up…

Asia-PacificBiotechnologyFinancialLicensing

Genzyme Framingham plant now cleared by US and EU regulators

24-01-2012

French drug major Sanofi (Euronext: SAN) said yesterday that the US Food and Drug Administration has…

BiotechnologyFabrazymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Rising interest of Big Pharma creates huge growth potential for outsourcing firms, says Frost & Sullivan

24-01-2012

Increasingly, big pharma is viewing the outsourcing of pharmaceutical manufacturing as a strategic move…

BiotechnologyEuropeFinancialMarkets & MarketingPharmaceutical

Spectrum upbeat on lymphoma drug Zevalin study

24-01-2012

US biotech firm Spectrum Pharmaceuticals (NasdaqGS: SPPI) yesterday announced results of a randomized…

BiotechnologyOncologyResearchSpectrum PharmaceuticalsZevalin

FDA lifts hold on Insmed Arikace trial

23-01-2012

USA-based biopharma company Insmed’s (Nasdaq CM: INSM) shares leapt 33.7% to $5.08 on Friday, after…

ArikaceBiotechnologyInsmedNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

Significant advances in biosimilar medicines claimed for Iran

23-01-2012

Iran is making significant advances in medicine production, especially in the fields of biosimilar and…

BiotechnologyGenericsMarkets & MarketingRest of the World

Thyroid cancer risk discovery by deCODE Genetics and collaborators

23-01-2012

Scientists at Iceland-based human genome specialist deCODE Genetics and academic collaborators from Iceland,…

BiotechnologydeCODE GeneticsOncologyResearch

EMA starts review of Gilenya; guidance on biosimilar interferon beta

23-01-2012

The European Medicines Agency has begun a review of the benefits and risks of Swiss drug major Novartis’…

BiotechnologyEuropeGenericsGilenyainterferon betaNeurologicalNovartisPharmaceuticalRegulation

FDA updates Tysabri label relating to anti-JCV

23-01-2012

The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

Alnylam looks to save $20 million via restructuring

22-01-2012

USA-based RNAi therapeutics specialist Alnylam Pharmaceuticals (Nasdaq: ALNY) said last week that it…

Alnylam PharmaceuticalsBiotechnologyFinancialManagement

Sandoz initiates two more Phase III biosimilar trials

20-01-2012

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…

AmgenBiotechnologyFilgrastimGenericsNovartisOncologypegfilgrastimResearchSandozZarzio

FDA backs Gilead’s Viread for children

20-01-2012

The US Food and Drug Administration has approved US biotech firm Gilead Sciences (Nasdaq: GILD) Viread…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationViread

1944 to 1968 of 2220 results

Back to top